EA202092893A1 - Фармацевтические композиции в лиофилизированной форме - Google Patents

Фармацевтические композиции в лиофилизированной форме

Info

Publication number
EA202092893A1
EA202092893A1 EA202092893A EA202092893A EA202092893A1 EA 202092893 A1 EA202092893 A1 EA 202092893A1 EA 202092893 A EA202092893 A EA 202092893A EA 202092893 A EA202092893 A EA 202092893A EA 202092893 A1 EA202092893 A1 EA 202092893A1
Authority
EA
Eurasian Patent Office
Prior art keywords
group
pharmaceutical compositions
disaccharide
lyophilized form
present
Prior art date
Application number
EA202092893A
Other languages
English (en)
Inventor
Оливер Денк
Original Assignee
Брес Терапьютикс Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Брес Терапьютикс Гмбх filed Critical Брес Терапьютикс Гмбх
Publication of EA202092893A1 publication Critical patent/EA202092893A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящее изобретение относится к лиофилизированной фармацевтической композиции для разведения в водном жидком носителе, содержащей a) липосомообразующие структуры, которые содержат i) терапевтически эффективное количество циклоспорина A (CsA); ii) мембранообразующее вещество, выбранное из группы фосфолипидов; iii) вещество, улучшающее растворимость, выбранное из группы неионогенных поверхностно-активных веществ; и b) по меньшей мере один дисахарид, выбранный из группы, состоящей из сахарозы, лактозы и трегалозы, причем по меньшей мере один дисахарид присутствует в количестве по меньшей мере 40 мас.% относительно общей массы лиофилизированной композиции.
EA202092893A 2018-06-27 2019-06-25 Фармацевтические композиции в лиофилизированной форме EA202092893A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18180177 2018-06-27
PCT/EP2019/066875 WO2020002353A1 (en) 2018-06-27 2019-06-25 Pharmaceutical compositions in lyophilized form

Publications (1)

Publication Number Publication Date
EA202092893A1 true EA202092893A1 (ru) 2021-04-19

Family

ID=62814888

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092893A EA202092893A1 (ru) 2018-06-27 2019-06-25 Фармацевтические композиции в лиофилизированной форме

Country Status (12)

Country Link
US (2) US20210244664A1 (ru)
EP (1) EP3813788A1 (ru)
JP (1) JP7401471B2 (ru)
CN (1) CN113038930A (ru)
AU (1) AU2019295027A1 (ru)
BR (1) BR112020026629A2 (ru)
CA (1) CA3104445A1 (ru)
CO (1) CO2021000223A2 (ru)
EA (1) EA202092893A1 (ru)
IL (1) IL279760A (ru)
MX (1) MX2020013831A (ru)
WO (1) WO2020002353A1 (ru)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62501631A (ja) 1985-01-11 1987-07-02 ザ・リ−ジェンツ・オブ・ジ・ユニバ−シィティ・オブ・カリフォルニア リポソ−ムの保持法
US4857319A (en) * 1985-01-11 1989-08-15 The Regents Of The University Of California Method for preserving liposomes
US4963362A (en) 1987-08-07 1990-10-16 Regents Of The University Of Minnesota Freeze-dried liposome mixture containing cyclosporin
JP2721041B2 (ja) 1991-04-19 1998-03-04 ネクスター・フアーマシユーテイカルズ・インコーポレイテツド 医薬調合品及び方法
AU6047996A (en) 1995-06-07 1996-12-30 Nexstar Pharmaceuticals, Inc. Liposomal cyclosporin formulations as agents for immunosuppr ession and multiple drug resistant indications
US5958378A (en) 1996-07-03 1999-09-28 Research Development Foundation High dose liposomal aerosol formulations containing cyclosporin A or budesonide
TW497974B (en) 1996-07-03 2002-08-11 Res Dev Foundation High dose liposomal aerosol formulations
IT1289938B1 (it) 1997-02-20 1998-10-19 Angelini Ricerche Spa Preparazione farmaceutica comprendente liposomi liofilizzati in cui e' incapsulato un principio attivo altamente insolubile in acqua e
EP1506032A1 (en) 2002-05-20 2005-02-16 Research Development Foundation Aerosol drug inhibition of lung metastases
EP1687635A2 (en) * 2003-11-26 2006-08-09 Applera Corporation Ligand-containing micelles and uses thereof
US7749485B2 (en) * 2004-06-03 2010-07-06 Bracco Research S.A. Liposomal assembly for therapeutic and/or diagnostic use
DE102006051512A1 (de) 2005-12-06 2007-06-14 Pari GmbH Spezialisten für effektive Inhalation Pharmazeutische Medikamentenzusammensetzungen mit Cyclosporin
BRPI0619565A2 (pt) 2005-12-08 2011-10-04 Wyeth Corp composições lipossÈmicas
EP1797895A1 (en) * 2005-12-16 2007-06-20 Pevion Biotech Ltd. An adjuvant system comprising virosomes and liposomes
US20110070294A1 (en) * 2009-09-23 2011-03-24 Javeri Indu Methods for the Administration of Drugs Using Liposomes
US20140127288A1 (en) * 2011-05-17 2014-05-08 Mitsubishi Gas Chemical Company, Inc. Liposome containing pyrroloquinoline quinone and sugar
EP3069711A1 (en) 2015-03-16 2016-09-21 PARI Pharma GmbH Cyclosporine formulations for use in the prevention or treatment of pulmonary chronic graft rejection

Also Published As

Publication number Publication date
JP7401471B2 (ja) 2023-12-19
CN113038930A (zh) 2021-06-25
WO2020002353A1 (en) 2020-01-02
CA3104445A1 (en) 2020-01-02
US20230301914A1 (en) 2023-09-28
JP2021528450A (ja) 2021-10-21
EP3813788A1 (en) 2021-05-05
AU2019295027A1 (en) 2020-12-24
US20210244664A1 (en) 2021-08-12
CO2021000223A2 (es) 2021-01-18
BR112020026629A2 (pt) 2021-03-23
MX2020013831A (es) 2021-03-25
IL279760A (en) 2021-03-01

Similar Documents

Publication Publication Date Title
MX2021011121A (es) Composiciones de limpieza que comprenden enzimas.
MX2019005088A (es) Formulaciones de virus adeno-asociados.
EA201992377A1 (ru) Стабильная композиция антитела
PE20200513A1 (es) Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y metodos para su uso
NZ730821A (en) Stable protein solution formulation containing high concentration of an anti-vegf antibody
RU2019110912A (ru) Стабилизированные небелковые композиции клостридиального токсина
PE20141159A1 (es) Metodos para tratar o prevenir trastornos relacionados con el colesterol
PH12021550770A1 (en) Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex
AR019082A1 (es) Composicion fungicida liquida concentrada, metodo para controlar el desarrollo de hongos, metodo para controlar el desarrollo de puccinia spp, septoria spp o mildiu pulverulento del trigo, y metodo para incrementar el rendimiento de cultivos infectados por enfermedades fungales
AR100268A1 (es) Formulación líquida que comprende compuesto neutralizante de gm-csf
HRP20220011T1 (hr) Nova stabilna formulacija za fxia protutijela
RS20160209A1 (sr) Ko-formulacije bifentrina sa visokotopivim agensima za zaštitu useva za upotrebu sa tečnim veštačkim đubrivima
MX2021002935A (es) Formulacion de anticuerpos contra csf-1r.
MX2020008125A (es) Composiciones que comprenden berberina.
AR084318A1 (es) Composicion que comprende particulas de insecticida-cera
MX2021001272A (es) Composiciones de bismuto-tiol y metodos de uso.
BR112018000701A2 (pt) composição de limpeza não corrosiva, altamente alcalina
MX2020008096A (es) Peptidos de la cadena b de la relaxina lipidados modificados y su uso terapeutico.
AR115365A1 (es) Formulaciones de anticuerpos anti-pd-l1 humanos
EA202092893A1 (ru) Фармацевтические композиции в лиофилизированной форме
EA202192860A1 (ru) Сиалилированные гликопротеины
JOP20210152A1 (ar) صياغة محلول بروتيني محتوية على تركيز عالٍ من جسم مضاد لـ vegf
ZA202204982B (en) Stable formulation of integrin antibody
AR107811A1 (es) Composiciones de limpieza neutras para pisos
EA202192646A1 (ru) Лиофилизированная композиция, содержащая соединение бензоазепина